Clinical and Angiographic Outcomes of the First Korean-made Sirolimus-Eluting Coronary Stent with Abluminal Bioresorbable Polymer

다국어 초록 (Multilingual Abstract)

Background and Objectives: This trial evaluated the safety and efficacy of the Genoss drug-eluting coronary stent.
Methods: This study was a prospective, multicenter, randomized trial with a 1:1 ratio of Genoss drug-eluting stent (DES)™ and Promus Element™. Inclusion criteria were the presence of stable angina, unstable angina, or silent ischemia. Angiographic inclusion criteria were de novo coronary stenotic lesion with diameter stenosis >50%, reference vessel diameter of 2.5–4.0 mm, and lesion length ≤40 mm. The primary endpoint was in-stent late lumen loss at 9-month quantitative coronary angiography follow-up. Secondary endpoints were in-segment late lumen loss, binary restenosis rate, death, myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), and stent thrombosis during 9 months of follow-up.
Results: We enrolled 38 patients for the Genoss DES™ group and 39 patients for the Promus Element™ group. In-stent late lumen loss at 9 months was not significantly different between the 2 groups (0.11±0.25 vs. 0.16±0.43 mm, p=0.567). There was no MI or stent thrombosis in either group. The rates of death (2.6% vs. 0%, p=0.494), TLR (2.6% vs. 2.6%, p=1.000), and TVR (7.9% vs. 2.6%, p=0.358) at 9 months were not significantly different.
Conclusion: This first-in-patient study of the Genoss DES™ stent showed excellent angiographic outcomes for in-stent late lumen loss and major adverse cardiac events over a 9-month follow-up.

참고문헌 (Reference)

1 Moses JW, "Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery" 349 : 1315-1323, 2003

2 Stone GW, "Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents" 356 : 998-1008, 2007

3 Chevalier B, "Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2" 2 : 188-195, 2009

4 Joner M, "Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk" 48 : 193-202, 2006

5 Meredith IT, "PLATINUM QCA: a prospective, multicentre study assessing clinical, angiographic, and intravascular ultrasound outcomes with the novel platinum chromium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses" 7 : 84-90, 2011

6 Zhang YJ, "NOBORI™ biodegradable-polymer biolimus-eluting stent versus durable-polymer drug-eluting stents: a meta-analysis" 174 : 151-153, 2014

7 Virmani R, "Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?" 109 : 701-705, 2004

8 Nebeker JR, "Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project" 47 : 175-181, 2006

9 Lüscher TF, "Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications" 115 : 1051-1058, 2007

10 Cutlip DE, "Clinical end points in coronary stent trials: a case for standardized definitions" 115 : 2344-2351, 2007

11 Meredith IT, "Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial" 2 : 977-985, 2009

12 Windecker S, "Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial" 372 : 1163-1173, 2008

13 Stefanini GG, "Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials" 33 : 1214-1222, 2012

14 Mintz GS, "American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents" 37 : 1478-1492, 2001

15 Morice MC, "A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization" 346 : 1773-1780, 2002

16 Serruys PW, "A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial" 1 : 58-65, 2005

17 Stone GW, "A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease" 350 : 221-231, 2004